These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32189864)

  • 1. Levodopa-Responsive Chorea: A Review.
    Farrenburg M; Gupta HV
    Ann Indian Acad Neurol; 2020; 23(2):211-214. PubMed ID: 32189864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease.
    Tripathi S; Sharma Y; Kumar D
    Curr Rev Clin Exp Pharmacol; 2024 Oct; ():. PubMed ID: 39415318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
    Curtis K; Sung V
    J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential diagnosis of Huntington's disease- neurological aspects of NKX2-1-related disorders.
    Skwara J; Nowicki M; Sharif L; Milanowski Ł; Dulski J; Elert-Dobkowska E; Skrzypek K; Hoffman-Zacharska D; Koziorowski D; Sławek J
    J Neural Transm (Vienna); 2024 Sep; 131(9):1013-1024. PubMed ID: 38916623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
    Heo YA; Scott LJ
    Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
    Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
    J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome.
    Reuter I; Hu MT; Andrews TC; Brooks DJ; Clough C; Chaudhuri KR
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):238-41. PubMed ID: 10644798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. deutetrabenazine for the treatment of chorea associated with Huntington's disease.
    Gupta H; Perkins W; Stark C; Kikkeri S; Kakazu J; Kaye A; Kaye AD
    Health Psychol Res; 2022; 10(5):36040. PubMed ID: 35774908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
    Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
    J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the management of Huntington's disease.
    Devadiga SJ; Bharate SS
    Bioorg Chem; 2022 Mar; 120():105642. PubMed ID: 35121553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa.
    Asmus F; Horber V; Pohlenz J; Schwabe D; Zimprich A; Munz M; Schöning M; Gasser T
    Neurology; 2005 Jun; 64(11):1952-4. PubMed ID: 15955952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TITF-1 gene mutation in a case of sporadic non-progressive chorea. Response to levodopa treatment.
    Fons C; Rizzu P; Garcia-Cazorla A; Martorell L; Ormazabal A; Artuch R; Campistol J; Fernandez-Alvarez E
    Brain Dev; 2012 Mar; 34(3):255-7. PubMed ID: 21555194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restless Legs Syndrome in NKX2-1-related chorea: An expansion of the disease spectrum.
    Iodice A; Carecchio M; Zorzi G; Garavaglia B; Spagnoli C; Salerno GG; Frattini D; Mencacci NE; Invernizzi F; Veneziano L; Mantuano E; Angriman M; Fusco C
    Brain Dev; 2019 Mar; 41(3):250-256. PubMed ID: 30352709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of drug therapy for chorea in NXK2-1-related disorders: Efficacy and safety evidence from case studies and series.
    Nou-Fontanet L; Martín-Gómez C; Isabel-Gómez R; Bachoud-Lévi AC; Zorzi G; Capuano A; ; Blasco-Amaro JA; Ortigoza-Escobar JD
    Eur J Neurol; 2023 Dec; 30(12):3928-3948. PubMed ID: 37694681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.